Engineered Non-Viral Gene Vectors for Combination Cancer Therapy: A Review

Journal of Biomedical Nanotechnology
Qianqian ZhengShuai Shi

Abstract

Following the US Food and Drug Administration's approval of gene therapy drugs, the great potential of disease gene therapy is once again being taken seriously. However, finding a safe and efficient gene delivery vector remains the biggest challenge to successful gene therapy. To overcome this, engineered non-viral gene delivery vectors are continually being developed, despite their lower efficiencies compared with viral vectors. However, the complex biological barriers and instability caused by charge interactions mean that, no major breakthroughs have been made in the clinical development of these non-viral gene vectors. Nevertheless, the functions of the engineered polymer gene carriers are continuously expanding, and success has been achieved with the combined use of therapeutic molecules and targeted delivery. These polymer gene-carrier vectors offer a broader choice of new treatments for diseases ever before.

Citations

Nov 22, 2019·Current Pharmaceutical Biotechnology·Songfeng ChenHongjian Liu
Dec 17, 2020·International Journal of Nanomedicine·Hongjia ZhangXingmei Duan
Jul 23, 2021·International Journal of Pharmaceutics·Alexandro AzevedoHenrique Faneca
Aug 11, 2021·Molecular Pharmaceutics·Xueyan ZhangKe Men

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Journal of Controlled Release : Official Journal of the Controlled Release Society
M HaiderH Ghandehari
Chemical Reviews
Meredith A Mintzer, Eric E Simanek
Symposium of the Pharmacology, Therapeutics and Toxicology Group, International Association for Dental Research
C C Gilkes
Cancer Science
Yasufumi Kaneda, Yasuhiko Tabata
© 2022 Meta ULC. All rights reserved